WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009143224) METHOD FOR THE TREATMENT OR PROPHYLAXIS OF LYMPHANGIOLEIOMYOMATOSIS (LAM) AND ANIMAL MODEL FOR USE IN LAM RESEARCH
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/143224    International Application No.:    PCT/US2009/044643
Publication Date: 26.11.2009 International Filing Date: 20.05.2009
IPC:
A01N 33/02 (2006.01), A61K 31/135 (2006.01)
Applicants: FOX CHASE CENTER CENTER [US/US]; 333 Cottman Avenue Philadelphia, PA 19111-2497 (US) (For All Designated States Except US).
HENSKE, Elizabeth, Petri [US/US]; (US) (For US Only).
YU, Jane [US/US]; (US) (For US Only)
Inventors: HENSKE, Elizabeth, Petri; (US).
YU, Jane; (US)
Agent: HAGAN, Patrick, J.; (US)
Priority Data:
61/054,714 20.05.2008 US
Title (EN) METHOD FOR THE TREATMENT OR PROPHYLAXIS OF LYMPHANGIOLEIOMYOMATOSIS (LAM) AND ANIMAL MODEL FOR USE IN LAM RESEARCH
(FR) PROCÉDÉ DE TRAITEMENT OU DE PROPHYLAXIE D'UNE LYMPHANGIOLÉIOMYOMATOSE (LAM) ET MODÈLE ANIMAL POUR UNE UTILISATION DANS LA RECHERCHE SUR LA LAM
Abstract: front page image
(EN)Treatment of lymphangioleiomyomatosis with the MEK1/2 inhibitor CI-1040 delayed the development of primary tumors and blocked the estrogen-induced lung metastases in treated animals. Such treatment also reduced the number of circulating ELT3 cells and decreased their lung colonization after intravenous injection.
(FR)Selon l’invention, un traitement d'une lymphangioléiomyomatose par l'inhibiteur de MEK1/2 CI-1040 a retardé le développement de tumeurs primaires et bloqué les métastases de poumon induites par œstrogène chez les animaux traités. Un tel traitement a également réduit le nombre de cellules ELT3 circulantes et diminué leur colonisation des poumons après injection intraveineuse.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)